Globeimmune reports promising results from Phase II hepatitis trial
The study compared GI-5005 plus standard of care (SOC) – pegylated-interferon plus ribavirin – versus SOC alone in patients with chronic genotype 1 hepatitis C infection. The GI-5005-02
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.